- Home
- GENE vs MBIO Comparison
GENE vs MBIO Comparison
Compare GENE & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENE
- MBIO
- Stock Information
- Founded
- GENE 1989
- MBIO 2015
- Country
- GENE Australia
- MBIO United States
- Employees
- GENE N/A
- MBIO N/A
- Industry
- GENE Biotechnology: Biological Products (No Diagnostic Substances)
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GENE Health Care
- MBIO Health Care
- Exchange
- GENE Nasdaq
- MBIO Nasdaq
- Market Cap
- GENE 2.5M
- MBIO 7.9M
- IPO Year
- GENE N/A
- MBIO N/A
- Fundamental
- Price
- GENE $0.77
- MBIO $0.22
- Analyst Decision
- GENE
- MBIO Strong Buy
- Analyst Count
- GENE 0
- MBIO 1
- Target Price
- GENE N/A
- MBIO $2.00
- AVG Volume (30 Days)
- GENE 20.9K
- MBIO 391.7K
- Earning Date
- GENE 11-13-2024
- MBIO 11-12-2024
- Dividend Yield
- GENE N/A
- MBIO N/A
- EPS Growth
- GENE N/A
- MBIO N/A
- EPS
- GENE N/A
- MBIO N/A
- Revenue
- GENE $6,453,696.00
- MBIO N/A
- Revenue This Year
- GENE N/A
- MBIO N/A
- Revenue Next Year
- GENE N/A
- MBIO N/A
- P/E Ratio
- GENE N/A
- MBIO N/A
- Revenue Growth
- GENE N/A
- MBIO N/A
- 52 Week Low
- GENE $0.67
- MBIO $0.13
- 52 Week High
- GENE $3.75
- MBIO $2.11
- Technical
- Relative Strength Index (RSI)
- GENE 46.51
- MBIO 40.01
- Support Level
- GENE $0.70
- MBIO $0.21
- Resistance Level
- GENE $0.83
- MBIO $0.24
- Average True Range (ATR)
- GENE 0.04
- MBIO 0.02
- MACD
- GENE 0.01
- MBIO 0.00
- Stochastic Oscillator
- GENE 62.50
- MBIO 20.25
About GENE Genetic Technologies Ltd ADS
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.